Xeris climbs on Amgen collaboration to develop eye disease treatment

Xeris Biopharma Holdings

10/01/2024 13:43

** Shares of therapy developer Xeris Biopharma   XERS.O 
rise ~7.9% to $2.60 premarket
    ** Co says it entered into a license agreement to develop,
manufacture and commercialize Amgen's eye disease treatment,
Tepezza, using co's XeriJect technology
    ** Says co has potential to receive $75 million in
development and regulatory milestones
    ** XeriJect is a formulation that helps in improving drug
delivery 
    ** Stock rose 76.7% in 2023

    

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))